Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JOHNSON & JOHNSONJNJ · Entity 2722 | EVP, WWC. Innovative Medicine | August 17, 2026 | August 18, 2026 |
| MCDONALDS CORPMCD · Entity 2849 | Director | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JOHNSON & JOHNSON
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 194,451.001 |
Ending reported balance
After 2026-08-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-17 · Exercise / conversion · Acquired 15,000 · Balance 209,451.001 Row 2 · 2026-08-17 · Sale · Disposed 15,000 · Balance 194,451.001 F1: This transaction was executed in multiple trades at prices ranging from $263.30 to $263.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $115.67 · Expires 2027-02-13 | Direct | 28,712 |
Reported balance
After 2026-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-17 · Exercise / conversion · Disposed 15,000 · Balance 28,712 F2: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $263.30 to $263.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date.
MCDONALDS CORP
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 4,108.7 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 129.9 · Balance 4,108.7 F1: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors' Deferred Compensation Plan (the "Plan"). F2: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4: Includes shares acquired through dividend reinvestment. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors' Deferred Compensation Plan (the "Plan").
F2: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation.
F3: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board.
F4: Includes shares acquired through dividend reinvestment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 23:12 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantPhantom Stock · Derivative | 129.9 | $230.94 | $29,999.11 |
DisclosureSEC source: 0001745938-26-000005 · form4.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,108.7 Underlying: Common Stock · 129.9 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors' Deferred Compensation Plan (the "Plan"). F2 · kind: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3 · derivative.exercise_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F3 · derivative.expiration_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4 · balance_after: Includes shares acquired through dividend reinvestment. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $115.67 | $0.00 |
DisclosureSEC source: 0000200406-26-000175 · wk-form4_1787092263.xml · derivative · entry 3 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,712 Underlying: Common Stock · 15,000 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | SaleCommon Stock | 15,000 | $263.36 | $3,950,400.00 |
DisclosureSEC source: 0000200406-26-000175 · wk-form4_1787092263.xml · nonDerivative · entry 2 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,451.001 F1 · price: This transaction was executed in multiple trades at prices ranging from $263.30 to $263.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 15,000 | $115.67 | $1,735,050.00 |
DisclosureSEC source: 0000200406-26-000175 · wk-form4_1787092263.xml · nonDerivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,451.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 21:56 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantPhantom Stock · Derivative | 110.99 | $270.31 | $30,001.71 |
DisclosureSEC source: 0001745938-26-000003 · form4.xml · derivative · entry 2 Taubert Jennifer L · CIK 0001745938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,949.25 Underlying: Common Stock · 110.99 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors' Deferred Compensation Plan (the "Plan"). F2 · kind: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3 · derivative.exercise_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F3 · derivative.expiration_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4 · balance_after: Includes shares acquired through dividend reinvestment. Read SEC document |
| March 31, 2026 Filed Jul 2, 2026 21:56 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantPhantom Stock · Derivative | 96.53 | $310.79 | $30,000.56 |
DisclosureSEC source: 0001745938-26-000003 · form4.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,813.63 Underlying: Common Stock · 96.53 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors' Deferred Compensation Plan (the "Plan"). F2 · kind: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3 · derivative.exercise_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F3 · derivative.expiration_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4 · balance_after: Includes shares acquired through dividend reinvestment. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 3,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · derivative · entry 14 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,940 Underlying: Common Stock · 3,940 shares Expires not disclosed F9 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F9 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F9 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F7 · balance_after: Each RSU represents a contingent right to receive one share of Company Common Stock. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 54,869 | $0.00 Strike: $243.45 | $0.00 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · derivative · entry 13 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,869 Underlying: Common Stock · 54,869 shares Expires 2036-02-15 F8 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 1,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · derivative · entry 12 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,692 Underlying: Common Stock · 1,847 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F6 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F6 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F7 · balance_after: Each RSU represents a contingent right to receive one share of Company Common Stock. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 1,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · derivative · entry 11 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,594 Underlying: Common Stock · 1,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. F5 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. F5 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. F7 · balance_after: Each RSU represents a contingent right to receive one share of Company Common Stock. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 945 | $243.45 | $230,060.25 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · nonDerivative · entry 8 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,451.001 F2 · shares: Shares withheld for payment of taxes upon vesting of RSUs. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 1,847 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · nonDerivative · entry 7 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,396.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 816 | $243.45 | $198,655.20 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · nonDerivative · entry 6 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,549.001 F2 · shares: Shares withheld for payment of taxes upon vesting of RSUs. Read SEC document |
| February 15, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 1,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · nonDerivative · entry 5 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,365.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionPerformance Share Units · Derivative | 27,412 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · derivative · entry 10 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,412 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 13, 2023. The PSUs convert into shares of Common Stock upon vesting. F3 · derivative.expiration_date: Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 13, 2023. The PSUs convert into shares of Common Stock upon vesting. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 1,302 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · derivative · entry 9 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. F1 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 13,547 | $244.55 | $3,312,918.85 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · nonDerivative · entry 4 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,771.001 F4 · shares: Shares withheld for payment of taxes upon vesting of PSUs. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 27,412 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · nonDerivative · entry 3 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,318.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 13, 2023. The PSUs convert into shares of Common Stock upon vesting. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 409 | $244.55 | $100,020.95 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · nonDerivative · entry 2 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,906.001 F2 · shares: Shares withheld for payment of taxes upon vesting of RSUs. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:11 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 1,302 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000037 · wk-form4_1771467106.xml · nonDerivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,315.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 01:45 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPerformance Share Units · Derivative | 27,412 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000030 · wk-form4_1770860741.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,412 Underlying: Common Stock · 27,412 shares Expires not disclosed F1 · derivative.exercise_price: Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 13, 2023. The PSUs convert into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 13, 2023. The PSUs convert into shares of Common Stock upon vesting. F2 · balance_after: The number of PSUs reflects the target number of PSUs originally granted on February 13, 2023, adjusted to reflect achievement relative to the performance conditions set forth in the award agreement, as certified on February 9, 2026. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 16:51 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantPhantom Stock · Derivative | 768.9 | $305.63 | $234,998.91 |
DisclosureSEC source: 0000063908-26-000016 · form4.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,696.03 Underlying: Common Stock · 768.9 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors' Deferred Compensation Plan (the "Plan"). F2 · kind: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3 · derivative.exercise_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F3 · derivative.expiration_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4 · balance_after: Includes shares acquired through dividend reinvestment. Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 18:34 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantPhantom Stock · Derivative | 98.72 | $303.89 | $30,000.02 |
DisclosureSEC source: 0000063908-25-000051 · form4.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,910.15 Underlying: Common Stock · 98.72 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors Deferred Compensation Plan (the "Plan"). F2 · kind: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3 · derivative.exercise_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F3 · derivative.expiration_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4 · balance_after: Includes shares acquired through dividend reinvestment. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 22:00 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 56,471 | $101.87 Strike: $101.87 | $5,752,700.77 |
DisclosureSEC source: 0000200406-25-000186 · wk-form4_1757109644.xml · derivative · entry 3 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,471 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Vested and exercisable one day after the third anniversary of the date of the grant. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 22:00 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | SaleCommon Stock | 56,471 | $177.81 | $10,040,882.63 |
DisclosureSEC source: 0000200406-25-000186 · wk-form4_1757109644.xml · nonDerivative · entry 2 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,013.001 F1 · price: This transaction was executed in multiple trades at prices ranging from $177.715 to $177.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 22:00 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 56,471 | $101.87 | $5,752,700.77 |
DisclosureSEC source: 0000200406-25-000186 · wk-form4_1757109644.xml · nonDerivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234,484.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 19:06 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantPhantom Stock · Derivative | 102.68 | $292.17 | $30,000.02 |
DisclosureSEC source: 0001567619-25-000358 · form4.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,692.43 Underlying: Common Stock · 102.68 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors Deferred Compensation Plan (the "Plan"). F2 · kind: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3 · derivative.exercise_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F3 · derivative.expiration_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4 · balance_after: Includes shares acquired through dividend reinvestment. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:54 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantPhantom Stock · Derivative | 96.04 | $312.37 | $30,000.01 |
DisclosureSEC source: 0001567619-25-000262 · form4.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,676.44 Underlying: Common Stock · 96.04 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors Deferred Compensation Plan (the "Plan"). F2 · kind: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3 · derivative.exercise_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F3 · derivative.expiration_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4 · balance_after: Includes shares acquired through dividend reinvestment. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 02:08 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 651 | $156.15 | $101,653.65 |
DisclosureSEC source: 0000200406-25-000052 · wk-form4_1739930875.xml · nonDerivative · entry 6 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,459.001 F2 · shares: Shares withheld for payment of taxes upon vesting of RSUs. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 02:08 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 1,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000052 · wk-form4_1739930875.xml · derivative · entry 11 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,188 Underlying: Common Stock · 1,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. F4 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. F4 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. F7 · balance_after: Each RSU represents a contingent right to receive one share of Company Common Stock. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 02:08 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 1,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000052 · wk-form4_1739930875.xml · nonDerivative · entry 5 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,110.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 22:35 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 5,539 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000080 · wk-form4_1740004513.xml · derivative · entry 2 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,539 Underlying: Common Stock · 5,539 shares Expires not disclosed F2 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F2 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. F2 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. Read SEC document |
| February 15, 2025 Filed Feb 19, 2025 22:35 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 89,781 | $0.00 Strike: $156.15 | $0.00 |
DisclosureSEC source: 0000200406-25-000080 · wk-form4_1740004513.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,781 Underlying: Common Stock · 89,781 shares Expires 2035-02-15 F1 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:08 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionPerformance Share Units · Derivative | 15,465 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000052 · wk-form4_1739930875.xml · derivative · entry 12 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,465 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 14, 2022. F5 · derivative.expiration_date: Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 14, 2022. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:08 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 4,053 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000052 · wk-form4_1739930875.xml · derivative · entry 10 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,053 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The RSUs awarded on February 14, 2022 vest three years after date of grant. The RSUs convert into shares of Common Stock upon vesting. F3 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The RSUs awarded on February 14, 2022 vest three years after date of grant. The RSUs convert into shares of Common Stock upon vesting. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:08 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 7,911 | $156.71 | $1,239,732.81 |
DisclosureSEC source: 0000200406-25-000052 · wk-form4_1739930875.xml · nonDerivative · entry 8 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,013.001 F6 · shares: Shares withheld for payment of taxes upon vesting of PSUs. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:08 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 15,465 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000052 · wk-form4_1739930875.xml · nonDerivative · entry 7 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,924.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 14, 2022. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:08 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 1,348 | $156.71 | $211,245.08 |
DisclosureSEC source: 0000200406-25-000052 · wk-form4_1739930875.xml · nonDerivative · entry 4 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,516.001 F2 · shares: Shares withheld for payment of taxes upon vesting of RSUs. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:08 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 4,053 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000052 · wk-form4_1739930875.xml · nonDerivative · entry 3 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,864.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Awarded under Issuer's Long-Term Incentive Plan. The RSUs awarded on February 14, 2022 vest three years after date of grant. The RSUs convert into shares of Common Stock upon vesting. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:08 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 410 | $155.26 | $63,656.60 |
DisclosureSEC source: 0000200406-25-000052 · wk-form4_1739930875.xml · nonDerivative · entry 2 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,811.001 F2 · shares: Shares withheld for payment of taxes upon vesting of RSUs. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:08 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 1,302 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000052 · wk-form4_1739930875.xml · derivative · entry 9 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,302 Underlying: Common Stock · 1,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. F1 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. F7 · balance_after: Each RSU represents a contingent right to receive one share of Company Common Stock. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 02:08 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 1,302 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000052 · wk-form4_1739930875.xml · nonDerivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,221.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 23:18 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPerformance Share Units · Derivative | 15,465 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-25-000025 · wk-form4_1739402273.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,465 Underlying: Common Stock · 15,465 shares Expires not disclosed F1 · derivative.exercise_price: Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 14, 2022. F1 · derivative.expiration_date: Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 14, 2022. F2 · balance_after: The total number of PSUs has been revised to reflect that certain PSUs, originally granted on February 14, 2022, were forfeited based on performance conditions set forth in the award agreement. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 00:41 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 58,504 | $100.06 Strike: $100.06 | $5,853,910.24 |
DisclosureSEC source: 0000200406-25-000013 · wk-form4_1739320870.xml · derivative · entry 3 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,504 shares Expires 2025-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Reflects the auto-exercise of options immediately prior to their expiration. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 00:41 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 47,436 | $153.12 | $7,263,400.32 |
DisclosureSEC source: 0000200406-25-000013 · wk-form4_1739320870.xml · nonDerivative · entry 2 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,919.001 F2 · shares: Shares withheld for payment of the exercise price and taxes in connection with the exercise of the options reported on this Form 4. Read SEC document |
| February 07, 2025 Filed Feb 12, 2025 00:41 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 58,504 | $100.06 | $5,853,910.24 |
DisclosureSEC source: 0000200406-25-000013 · wk-form4_1739320870.xml · nonDerivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,355.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the auto-exercise of options immediately prior to their expiration. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:53 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantPhantom Stock · Derivative | 700.47 | $289.89 | $203,059.25 |
DisclosureSEC source: 0001567619-25-000018 · form4.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,565.65 Underlying: Common Stock · 700.47 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Directors' Deferred Compensation Plan (the "Plan"). F2 · kind: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3 · derivative.exercise_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F3 · derivative.expiration_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4 · balance_after: Includes shares acquired through dividend reinvestment. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 20:38 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantPhantom Stock · Derivative | 98.52 | $304.51 | $30,000.33 |
DisclosureSEC source: 0000063908-24-000141 · form4.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,751.1 Underlying: Common Stock · 98.52 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors Deferred Compensation Plan (the "Plan"). F2 · kind: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3 · derivative.exercise_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F3 · derivative.expiration_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4 · balance_after: Includes shares acquired through dividend reinvestment. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 20:37 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantPhantom Stock · Derivative | 117.72 | $254.84 | $29,999.76 |
DisclosureSEC source: 0000063908-24-000110 · form4.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,643.23 Underlying: Common Stock · 117.72 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors Deferred Compensation Plan (the "Plan"). F2 · kind: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3 · derivative.exercise_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F3 · derivative.expiration_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4 · balance_after: Includes shares acquired through dividend reinvestment. Read SEC document |
| March 29, 2024 Filed Apr 2, 2024 20:04 UTC | MCDONALDS CORP MCD · Entity 2849 | GrantPhantom Stock · Derivative | 106.4 | $281.95 | $29,999.48 |
DisclosureSEC source: 0000063908-24-000086 · form4.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,515.53 Underlying: Common Stock · 106.4 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors Deferred Compensation Plan (the "Plan"). F2 · kind: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3 · derivative.exercise_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F3 · derivative.expiration_date: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4 · balance_after: Includes shares acquired through dividend reinvestment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.